Related Experiment Videos
[Bladder tumors and molecular markers. Current status and perspectives]
Vincent Molinié1, Elisabeth Longchampt, Delphine Ouazana
1Service de Pathologie, Hôpital FOCH, 92151 Suresnes Cedex. v.molinie@hopital-foch.org
Annales De Pathologie
|November 5, 2003
Summary
Superficial bladder tumors frequently recur or progress despite treatment. Ki67 expression is a promising, reproducible marker for predicting bladder cancer progression, outperforming p53.
Area of Science:
- Uro-oncology
- Cancer biology
Context:
- Bladder tumors represent the second most common urological cancer in France, with 15,000 new cases annually.
- Current treatments, including trans-urethral resection with immunotherapy or chemotherapy, face challenges due to tumor recurrence and progression risks.
Purpose:
- To evaluate biological markers for predicting superficial bladder tumor recurrence and progression.
- To compare the utility of Ki67, p53, and EGFR as prognostic markers.
Summary:
- Histological features like stage and grade remain primary prognostic indicators, as molecular markers have not yet replaced them.
- While microsatellite instability shows promise, its clinical application is limited.
- Among evaluated markers, Ki67 expression demonstrates the most reproducible and reliable indicator for bladder cancer progression compared to p53 and EGFR.
Impact:
- Identifies Ki67 as a potentially valuable and reproducible marker for predicting bladder tumor progression.
- Highlights the need for further research into novel tissue analysis techniques for identifying robust biological and therapeutic markers.
- Aims to improve patient management by offering more accurate prognostic information for superficial bladder tumors.